1. Introduction {#sec1}
===============

Developmental delay/intellectual disability (DD/ID) affects approximately 3% of the general population \[[@B1]\]. In China, 11,820,000 people were diagnosed with DD/ID, of whom 954,000 were younger than 6 years of age \[[@B2]\]. Taking care of a patient with DD/ID exerts a substantial financial and emotional burden on his/her family and society. Approximately more than half of DD/ID cases resulted from genetic etiologies, including chromosomal abnormalities, microduplication or microdeletion syndromes, and monogenic disorders \[[@B3]\]. Other etiologies include teratogenic exposures, perinatal asphyxia, infections, etc. \[[@B4]\].

Submicroscopic chromosomal aberrations (copy number variants, CNVs) play a significant role in the pathogenesis of DD/ID, and the diagnostic yield of chromosomal microarray analysis- (CMA-) detected CNVs associated with these disorders ranges from 12% to 29% \[[@B5]--[@B8]\]. Currently, the clinical utility of CMA has been recognized by several professional societies and has been recommended as the first-tier genetic test for patients with unexplained DD/ID, autism spectrum disorders (ASDs), and/or multiple congenital anomalies (MCAs) \[[@B9]--[@B12]\]. In this study, we investigated 633 Chinese children with unexplained DD/ID combined with other conditions by the Affymetrix® CytoScan™ 750K Array over a period of 5 years and extensively assessed the value of CMA for the diagnosis of children with DD/ID.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

A total of 633 Chinese patients with varying degrees of DD/ID (359 males; 274 females), with ages from 3 months to 17 years, were recruited from the Department of Neurological Rehabilitation at West China Second University Hospital, Sichuan University, from January 2014 to March 2019. All patients were classified into 4 subgroups: isolated DD/ID (*n* = 332), DD/ID with MCA (*n* = 149), isolated ASD (*n* = 81), and DD/ID with epilepsy (*n* = 71).

The detailed evaluations of the patients included prenatal/birth history, family history, pedigree, physical examinations, and imageological examination. The inclusive criteria were as follows: DD/ID diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) with IQ/DQ \< 70 assessed by the Gesell Development Scale, the Wechsler Preschool and Primary Scale Intelligence, or the Wechsler Intelligence Scale for Children. The exclusion criteria were as follows: (1) history of hypoxia, toxication, central nervous system infection, and cranial trauma; (2) evidence of recognizable inherited metabolic disorder; (3) typical clinical manifestation of Rett syndrome for female patients; (4) mutations in the FMR1 gene for male patients; and (5) fetus or newborns with multiple malformations.

The peripheral blood samples of the patients were analyzed by CMA. Informed consent was obtained from their mentally healthy parents before detection. In addition, the peripheral blood samples of their parents underwent CMA to determine whether the CNVs of the patients were inherited or *de novo* to determine the clinical significance. The research was approved by the Medical Ethics Committee of West China Second University Hospital, Sichuan University.

2.2. Chromosomal Microarray Analysis {#sec2.2}
------------------------------------

Whole genomic DNA was extracted from peripheral blood cells of each patient and his or her parents using QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) and subjected to CMA-single nucleotide polymorphism (SNP) array analysis by using the Affymetrix® CytoScan™ 750K Array (Affymetrix, Santa Clara, CA, USA). The procedure was described in our previous publication \[[@B13]\].

When the fragment size of absence of heterozygosity (AOH) was larger than one-third of the chromosome, analysis software UPD tool_0.2 was used to separate the AOH into uniparental disomy (UPD) or consanguinity by comparison with the parental results.

The detected CNVs were systematically evaluated for clinical significance. The procedure was also described in our previous publication \[[@B13]\].

2.3. Chromosomal Karyotyping {#sec2.3}
----------------------------

When a gain and a loss of more than 5 Mb were simultaneously detected at one end of two different chromosomes or at the both ends of a single chromosome in one sample, peripheral blood samples of the normal parents were karyotyped to confirm whether the parents had chromosomal balanced translocations or inversions.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical analysis was performed by using SPSS software, version 24. The frequency of pCNVs was compared among subgroups of isolated DD/ID, DD/ID with MCA, DD/ID with ASD, and DD/ID with ASD by using the chi-square test. A value of *p* \< 0.05 was considered to indicate statistical significance.

3. Results {#sec3}
==========

3.1. Diagnostic Yields of pCNVs {#sec3.1}
-------------------------------

We detected 149 pCNVs (including 5 UPDs) in 127 cases (65 males; 62 females), accounting for 20.06% of the series ([Table 1](#tab1){ref-type="table"}). These pCNVs, including 100 deletions and 44 duplications, were highly variable in size, ranging from 223 kb to 102,400 kb ([Table 2](#tab2){ref-type="table"}).

Fifty-two pCNVs (34.90%, 52/149) were detected in patients with MCA. In the subgroup of MCA, several clinical manifestations were found, including facial dysmorphic features, growth disorders, micro/macrocephaly, cleft palate, ear deformity, abnormal hands or feet, abnormal heart morphology, and abnormal genital system. In addition, 60 pCNVs (18.07%, 60/332) were detected in patients with isolated DD/ID, 3 pCNVs (3.70%, 3/81) were detected in patients with isolated ASD, and 12 pCNVs (16.90%, 12/71) were detected in patients with epilepsy. The proportion of pCNVs detected in patients with MCA was significantly higher than that in patients with isolated DD/ID (*p* ≤ 0.001 (34.90% vs. 18.07%)) or patients with isolated ASD (*p* ≤ 0.001 (34.90% vs. 3.70%)) or patients with epilepsy (*p*=0.004 (34.90% vs. 16.90%)). The proportion of pCNVs in patients with isolated ASD was significantly lower than that in patients with isolated DD/ID (*p* ≤ 0.001 (3.70% vs. 18.07%)) or patients with ASD (*p*=0.007 (3.70% vs. 16.90%)).

3.2. Microdeletion/Microduplication Syndromes {#sec3.2}
---------------------------------------------

Of the 127 cases with abnormal results, 76 cases had 35 types of microdeletion/microduplication syndromes (59.84%), including Williams-Beuren syndrome, Angelman syndrome, Prader--Willi syndrome, 22q11 deletion syndrome (velocardiofacial/DiGeorge syndrome), and Wolf--Hirschhorn syndrome. Twenty-nine microdeletion/microduplication syndromes were detected in patients with isolated DD/ID (8.73%, 29/332), 40 in patients with MCA (26.85%, 40/149), 3 in patients with isolated ASD (3.70%, 3/81), and 5 in patients with epilepsy (7.04%, 5/71) ([Table 3](#tab3){ref-type="table"}).

Most of the microdeletion/microduplication syndromes were *de novo* (63/77), including 2 patients with AS caused by paternal UPD15 and 3 patients with Russell--Silver syndrome (RSS) caused by maternal UPD7. However, some patients inherited neurocognitive disorder susceptibility loci, including 16p11.2 recurrent microdeletion (1/3) and 16p13.11 recurrent microduplication/microdeletion (2/4) from their normal parents. Two male patients had maternally inherited Xq28 (MECP2) duplication, and 1 male patient had maternally inherited Xp11.22-linked intellectual disability. All 3 cases with 15q11-q13 duplication syndrome were inherited from their normal mothers, in which one also suffered from 16p11.2 recurrent microdeletion inherited from her normal father ([Figure 1(a)](#fig1){ref-type="fig"}).

3.3. Submicroscopic Unbalance Rearrangements {#sec3.3}
--------------------------------------------

Of the 127 cases with abnormal results, 18 cases were detected with submicroscopic unbalance rearrangements (14.17%), including 10 cases inherited from parental balanced translocations or pericentric inversions ([Figure 1(b)](#fig1){ref-type="fig"}). Fifteen cases had subtelomeric aberrations at the end of two different chromosomes, of which 8 cases were inherited from normal parents with balanced translocations confirmed by karyotyping. Three cases had subtelomeric aberrations at both ends of the same chromosome, of which 2 cases were inherited from normal parents with pericentric inversions confirmed by karyotyping.

4. Discussion {#sec4}
=============

The establishment of genetic etiological diagnoses for DD/ID children is usually challenging due to the high frequency of relatively nonspecific symptoms shared by numerous potential syndromes. We identified pCNVs in 20.06% of cases, which was comparable to other reported series \[[@B8], [@B14]--[@B17]\]. Interestingly, our study revealed some new findings with certain clinical significance.

4.1. More Deletions than Duplications in pCNVs {#sec4.1}
----------------------------------------------

In our study, the proportion of deletions was extremely higher than duplications in pCNVs. This finding is consistent with the notion of Ruderfer et al. \[[@B18]\] that many duplications present in the human genome are benign, and most phenotypically normal individuals possess a higher number of duplications than deletions. The dosage-sensitive genes have the ability to cause phenotypes \[[@B9]\]. In our study, 32 genes were confirmed with "sufficient evidence for haploinsufficiency" in the pathogenic deletions, while only 2 genes were confirmed with "sufficient evidence for triplosensitivity" in the pathogenic duplications (<https://www.clinicalgenome.org/>), which influenced the phenotypes of these patients. Thus, deletions contributed more pathogenic interpretations than duplications.

4.2. Diagnostic Yields Associated with the Phenotypes {#sec4.2}
-----------------------------------------------------

The diagnostic yield of pCNVs (including microdeletion/microduplication syndromes) in the MCA subgroup was significantly higher than that in the other 3 subgroups, which implied that severe and complex phenotypes, such as dysmorphology or congenital anomalies, tend to have a higher likelihood of identifying a genetic etiology \[[@B4]\]. Case 92 is a 13-year-old female who has mild ID, specifically a learning disability with a cleft palate. CMA revealed a 5242-kb duplication in the 15q11.2q13.1 (15q11-q13 duplication syndrome) inherited from her normal mother and a 748-kb deletion in 16p11.2 (16p11.2 recurrent microdeletion) inherited from her normal father. Evidence suggests that maternally derived 15q11.2q13.1 duplications are more frequently associated with abnormal phenotypes \[[@B19]\]. Weiss et al. \[[@B20]\] reported that the phenotype of 16p11.2 recurrent microdeletion is characterized by DD, ID, and/or ASD. It is rare that one patient suffers from two different microdeletion/microduplication syndromes. We hypothesized that both the duplication and deletion contributed to the phenotype of the patient. The probability of her parents having another baby with one of the pCNVs or for both is extremely as high as 75%. Wolfe et al. \[[@B21]\] identified that 16p11.2 deletions and 15q11.2q13.1 duplications had incomplete penetrance with high frequencies in neurodevelopmental disorders; however, they sometimes can be observed in healthy controls. So, the phenotype of the baby with pCNV(s) could not be confirmed before birth.

In the isolated DD/ID subgroup and DD/ID with epilepsy subgroup, the diagnostic yields of pCNVs were significantly lower than those of the MCA subgroup but significantly higher than those of the isolated ASD subgroup. The more phenotypes the patients had, such as epilepsy, the higher the likelihood of finding a genetic etiology \[[@B9]\]. However, the diagnostic yields of pCNVs between these two subgroups were not statistically significant. Next-generation sequencing (NGS) also contributes to the identification of epilepsy caused by monogenic mutations \[[@B22]\], which might be omitted by CMA.

The diagnostic yield of pCNVs was significantly lower in the patients with isolated ASD than in the other 3 subgroups, which was consistent with the results of Ho et al. \[[@B16]\]. We assumed that some other genetic etiologies, such as single-gene disorders, may contribute to the pathogenesis of ASD, which requires further investigation. We detected 3 microdeletion/microduplication syndromes in this subgroup, including Smith--Magenis syndrome, Potocki--Lupski syndrome, and 2q37 monosomy, which were reported in the previous studies \[[@B23], [@B24]\].

Thus, we believe that the correct genetic diagnosis confirmed by CMA is imperative to medical management and prognostic evaluation of patients with DD/ID.

4.3. Assessment of Recurrence Risks {#sec4.3}
-----------------------------------

In our study, microdeletion/microduplication syndromes were detected in 76 patients. As most of the syndromes are *de novo* (63/77), the recurrence risk of these sporadic syndromes is extremely low. However, the parents of the DD/ID patients with maternally derived 15q11-q13 duplication (Cases 23, 24, and 92) or some parentally derived recurrent CNVs such as 16p11.2 microdeletion (Case 92) or 16p13.11 microduplication/microdeletion (Cases 22 and 86) have a recurrence risk of 50%. In addition, the parents of male patients with maternally derived X-chromosomal aberrations including Xp22.31 deletion, Xq28 duplication, or Xp11.22 duplication have a recurrence risk of 25%. Hence, the CMA results of these parents are more vital to evaluate the recurrence risk in reproduction.

In the 127 cases with pCNVs, 18 cases (14.17%) were identified with submicroscopic subtelomeric aberrations, including 7 patients suffering from microdeletion/microduplication syndromes, which was consistent with the results of Cheng et al. \[[@B25]\]. In the 18 cases, 8 families were confirmed with parental balanced translocations and 2 families were confirmed with pericentric inversions by karyotyping. These families have an extremely high risk of having another child with submicroscopic subtelomeric aberrations induced DD/ID (10/18). Conventional cytogenetics can only recognize chromosomal rearrangements with a limited resolution of 5∼10 Mb \[[@B9]\]. There were still 8 cases diagnosed as *de novo* submicroscopic subtelomeric aberrations by comparing with the karyotypes of their parents. These parents should be further tested whether they have balanced translocations or pericentric inversions by locus specific FISH probes according to the results of CMA. Fortunately, all the 18 families may possibly have a healthy child if effective genetic counseling was given based on reasonable techniques of prenatal or preimplantational diagnosis.

4.4. Limitations of CMA {#sec4.4}
-----------------------

Parental study is usually indispensable because it not only helps with the interpretation of the clinical significance of CNVs but also contributes to genetic counseling and the evaluation of recurrence risk of genetic abnormalities \[[@B26]\]. However, even though the results of normal parents were compared with their children, there was still 1.11% VUS in our study. In general, the rate of VUS will decrease as more CMA results are obtained from the normal parents. The establishment of a normal individual CMA database might be helpful to address this issue.

CMA has been confirmed as a vital technology to offer extremely higher diagnostic yield compared with chromosomal karyotype analysis in DD/ID. However, the genetic etiology of approximately 80% of patients remains unknown. Development of NGS offers another option for the genetic diagnosis of DD/ID. Currently, with an increased number of pathogenic mutations of genes associated with DD/ID detected by NGS, the diagnostic yield could be further improved by 20∼30% \[[@B27], [@B28]\]. A combination of CMA and NGS could be a comprehensive strategy, but the cost-effectiveness should be considered.
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###### 

Summary of CMA results in 633 patients.

  Category              Microarray results (%)   Total                    
  --------------------- ------------------------ ---------- ------------- -----
  Isolated DD/ID        60 (18.07)               5 (1.51)   267 (80.42)   332
  DD/ID with MCA        52 (34.90)               0 (0.00)   97 (65.10)    149
  DD/ID with ASD        3 (3.70)                 0 (0.00)   78 (96.30)    81
  DD/ID with epilepsy   12 (16.90)               2 (2.82)   57 (80.28)    71
  Total                 127 (20.06)              7 (1.11)   499 (78.83)   633

DD: developmental delay; ID: intellectual disability; MCA: multiple congenital anomaly; ASD: autism spectrum disorder.

###### 

Characteristics of pCNVs detected by CMA among the 127 patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Clinical feature                                                                                            Age    Gender   CMA results                                              Sizes of CNVs (kb)   Copy number            Syndromes                                                                            OMIM gene                Inherited or *de novo*
  ----- ----------------------------------------------------------------------------------------------------------- ------ -------- -------------------------------------------------------- -------------------- ---------------------- ------------------------------------------------------------------------------------ ------------------------ ----------------------------------------------------------------
  1     ID                                                                                                          17 y   F        arr\[GRCh37\] 12p12.1(21369190_25634175)x1               3995                 Loss                   Lamb-Shaffer syndrome                                                                SOX5                     *de novo*

  2     DD                                                                                                          3 y    F        arr\[GRCh37\] 4p16.3p16.1(68345_8066350)x1               7998                 Loss                   Wolf--Hirschhorn syndrome                                                                                     *de novo*

  3     ID                                                                                                          5 y    M        arr\[GRCh37\] 7q11.23(72723370_74136633)x1               1413                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  4     DD                                                                                                          4 y    M        arr\[GRCh37\] Xq28(153118233_153878720)x2                760                  Gain                   Xq28 (MECP2) duplication                                                             MECP2                    Inherited from normal mother

  5     ID                                                                                                          5 y    M        arr\[GRCh37\] 15q11.2q26.3(22817870_102397317)hmz        79,579               LOH (paternal UPD15)   Angelman syndrome                                                                    UBE3A                    *de novo*

  6     DD                                                                                                          4 y    M        arr\[GRCh37\] 7q11.23(72718123_74136633)x1               1419                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  7     DD                                                                                                          19 m   M        arr\[GRCh37\] 15q11.2q13.1(23632677_28704050)x1          5071                 Loss                   Angelman syndrome                                                                    UBE3A                    *de novo*

  8     ID                                                                                                          16 y   F        arr\[GRCh37\] 7q11.23(72718123_74141494)x1               1423                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  9     DD                                                                                                          16 m   M        arr\[GRCh37\] 11p11.2(44506359_47897669)x1               3391                 Loss                   Potocki--Shaffer syndrome                                                            MYBPC3                   *de novo*

  10    ID                                                                                                          6 y    M        arr\[GRCh37\] 15q11.2q13.1(23290787_28526905)x1          5147                 Loss                   Angelman syndrome                                                                    UBE3A                    *de novo*

  11    ID                                                                                                          7 y    M        arr\[GRCh37\] Xq28(153030708_155233098)x2                2202                 Gain                   Xq28 (MECP2) duplication                                                             MECP2                    Inherited from normal mother

  12    ID                                                                                                          16 y   F        arr\[GRCh37\] 15q11.2q26.3(22817870_102397317)hmz        79,579               LOH (paternal UPD15)   Angelman syndrome                                                                    UBE3A                    *de novo*

  13    ID                                                                                                          6 y    M        arr\[GRCh37\] 7q11.23 (72611954_75147402)x1              1745                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  14    ID                                                                                                          5 y    M        arr\[GRCh37\] 16p13.3(85880_2045435)x1                   1960                 Loss                   ATR-16 syndrome                                                                                               *de novo*

  15    DD                                                                                                          17 m   F        arr\[GRCh37\] 7q11.23(72692112_74184702)x1               1496                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  16    ID                                                                                                          16 y   F        arr\[GRCh37\] 22q13.33(50974299_51197766)x1              223                  Loss                   22q13 deletion syndrome (Phelan--Mcdermid syndrome)                                  SHANK3                   *de novo*

  17    ID                                                                                                          9 y    F        arr\[GRCh37\] 17p11.2 (16761814_20304118)x3              3542                 Gain                   Potocki--Lupski syndrome (17p11.2 duplication syndrome)                                                       *de novo*

  18    DD                                                                                                          9 m    F        arr\[GRCh37\] 7q11.23(72723370_74136633)x1               1413                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  19    ID                                                                                                          6 y    F        arr\[GRCh37\] 22q13.31q13.33(48234841_51197766)x1        2963                 Loss                   22q13 deletion syndrome (Phelan--Mcdermid syndrome)                                  SHANK3                   *de novo*

  20    DD                                                                                                          13 m   F        arr\[GRCh37\] 22q11.21(18919477_21436003)x3              2516                 Gain                   22q11 duplication syndrome                                                                                    *de novo*

  21    ID                                                                                                          9 y    M        arr\[GRCh37\] 7q11.23(72723370_74136633)x1               1413                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  22    ID                                                                                                          12 y   M        arr\[GRCh37\] 16p13.11(14892975_16538596)x3              1646                 Gain                   16p13.11 recurrent microduplication (neurocognitive disorder susceptibility locus)                            Inherited from normal mother

  23    ID                                                                                                          5 y    F        arr\[GRCh37\] 15q11.2q13.1(22770421_28560664)x3          5790                 Gain                   15q11-q13 duplication syndrome                                                                                Inherited from normal mother

  24    ID                                                                                                          17 y   F        arr\[GRCh37\] 15q11.2q13.1(22770421_28526905)x3          5756                 Gain                   15q11-q13 duplication syndrome                                                                                Inherited from normal mother

  25    DD                                                                                                          13 m   F        arr\[GRCh37\] 5q23.3q31.2(129203365_139475046)x3         10,272               Gain                                                                                                                                 *de novo*

  26    ID                                                                                                          16 y   F        arr\[GRCh37\] 8p23.3p23.1(158048_9781509)x1              9623                 Loss                   8p23.1 deletion syndrome                                                             CSMD1                    de novo

  27    ID                                                                                                          9 y    F        arr\[GRCh37\] 7q36.1q36.3(151376795_159119707)x1         7743                 Loss                                                                                                        SHH; KMT2C; DPP6; MNX1   *de novo*

  28    DD                                                                                                          3 y    M        arr\[GRCh37\] 1q43q44(239750391_249224684)x1             9474                 Loss                   1q43-q44 deletion syndrome                                                           CHRM3; AKT3; HNRNPU      *de novo*

  29    ID                                                                                                          12 y   M        arr\[GRCh37\] 3q23q25.1(141486765_151354816)x1           9868                 Loss                                                                                                        ZIC1; ZIC4               *de novo*

  30    DD                                                                                                          4 y    F        arr\[GRCh37\] 18p11.32p11.21(136227_12342194)x1          12,206               Loss                                                                                                        TGIF1                    *de novo*

  31    ID                                                                                                          16 y   F        arr\[GRCh37\] 11q24.2q25(124419306_134937416)x1          10,518               Loss                                                                                                                                 *de novo*

  32    ID                                                                                                          17 y   F        arr\[GRCh37\] 3q27.3q29(187068732_194767726)x1           7699                 Loss                                                                                                        TP63; FGF12              *de novo*

  33    DD                                                                                                          8 m    M        arr\[GRCh37\] 10q26.13q26.3(123584147_135426386)x1       11,842               Loss                                                                                                        EBF3                     *de novo*

  34    DD                                                                                                          3 y    M        arr\[GRCh37\] 11q14.1(77492774_85312824)x1               7820                 Loss                                                                                                        DLG2                     *de novo*

  35    DD                                                                                                          4 y    M        arr\[GRCh37\]Mosaic 15q14q24.1(35050247_75972909)x1.63   40,923               Loss (Mosaic)          15q24 recurrent microdeletion syndrome                                                                        *de novo*

  36    DD                                                                                                          4 y    M        arr\[GRCh37\] 1q42.13q44(228801122_249181598)x3          20,380               Gain                                                                                                                                 *de novo*

  37    ID                                                                                                          6 y    M        arr\[GRCh37\] 1q42.13q44(229917977_249224684)x3          19,307               Gain                                                                                                                                 *de novo*

  38    DD                                                                                                          3 y    F        arr\[GRCh37\] 12p13.33q12(173786_40931729)x3             40,758               Gain                   Partial chromosome 12\                                                                                        *de novo*
                                                                                                                                                                                                                                         trisomy                                                                                                       

  39    ID                                                                                                          8 y    M        arr\[GRCh37\] Xp21.3p11.23(27954516_48270449)x1          20,316               Loss                   Xp11.23 region (includes MAOA and MAOB)                                                                       *de novo*

  40    ID                                                                                                          10 y   F        arr\[GRCh37\] 18q21.32q23(58617060_78013728)x1           19,847               Loss                                                                                                                                 *de novo*

  41    ID                                                                                                          16 y   F        arr\[GRCh37\] 11q14.2q22.3(87455736_109777755)x1         22,322               Loss                                                                                                                                 *de novo*

  42    DD                                                                                                          4 y    F        arr\[GRCh37\] 4p16.3p15.31(290685_18118492)x3            17,828               Gain                   4p16.3 terminal (Wolf--Hirschhorn syndrome) region                                                            *de novo*

                                                                                                                                    arr\[GRCh37\] 4q34.1q35.2(176152080_190957460)x1         14,805               Loss                                                                                                                                  

  43    DD                                                                                                          3 y    M        arr\[GRCh37\] 8p23.3p23.1(158048_10915395)x3             10,757               Gain                   8p23.1 duplication syndrome                                                          SOX7                     *de novo*

                                                                                                                                    arr\[GRCh37\] 9p24.3p24.1(208454_6308953)x1              6100                 Loss                                                                                                        DMRT1                     

  44    ID                                                                                                          8 y    M        arr\[GRCh37\] 4p16.3p16.1(68345_9514461)x3               9446                 Gain                   4p16.3 terminal (Wolf--Hirschhorn syndrome) region                                                            Paternal balanced\
                                                                                                                                                                                                                                                                                                                                                       translocation 46,XY,t(4; 8) (p16q23)

                                                                                                                                    arr\[GRCh37\] 8p23.3p23.1(158048_7044046)x1              6886                 Loss                                                                                                        CSMD1                     

  45    ID                                                                                                          17 y   F        arr\[GRCh37\] 9p24.3p24.1(208454_8748943)x3              8540                 Gain                                                                                                                                 *de novo*

                                                                                                                                    arr\[GRCh37\] 18q22.1q23(65906752_78013728)x1            12,107               Loss                                                                                                                                  

  46    ID                                                                                                          3 y    M        arr\[GRCh37\] 6q27(169727875_170914297)x3                1186                 Gain                                                                                                                                 *de novo*

                                                                                                                                    arr\[GRCh37\] 13q33.3q34(107636085_115107733)x1          7472                 Loss                                                                                                        CHAMP1; BSVD2             

  47    ID                                                                                                          17 y   M        arr\[GRCh37\] 11q25(131001110_134937416)x1               3936                 Loss                                                                                                                                 Maternal balanced\
                                                                                                                                                                                                                                                                                                                                                       translocation 46,XX,t(11; 18) (q25; q21.2)

                                                                                                                                    arr\[GRCh37\] 18q21.2q23(50912872_78013728)x3            27,101               Gain                                                                                                                                  

  48    ID                                                                                                          16 y   F        arr\[GRCh37\] 9p24.3p21.1(208454_30555044)x3             30,347               Gain                                                                                                                                 Paternal balanced\
                                                                                                                                                                                                                                                                                                                                                       translocation 46,XY,t(9; 18) (p21; p11.3)

                                                                                                                                    arr\[GRCh37\] 18p11.32p11.31(136227_5485196)x1           5349                 Loss                                                                                                        TGIF1                     

  49    ID                                                                                                          7 y    M        arr\[GRCh37\] 3p26.3p26.1(61891_5189701)x1               5128                 Loss                                                                                                        CNTN4; CNTN6; ITPR1      *de novo*

                                                                                                                                    arr\[GRCh37\] 7q33q36.3(134287922_159119707)x3           24,832               Gain                                                                                                        SHH                       

  50    DD                                                                                                          3 y    F        arr\[GRCh37\] 6q25.3q27(159131590_170914297)x3           11,783               Gain                                                                                                                                 Maternal balanced\
                                                                                                                                                                                                                                                                                                                                                       translocation 46,XX,t(6; 10) (q25.3; p15.3)

                                                                                                                                    arr\[GRCh37\] 10p15.3(100047_1947393)x1                  1847                 Loss                                                                                                        ZMYND11                   

  51    ID                                                                                                          16 y   F        arr\[GRCh37\] 9p24.3p13.3(208454_33702198)x3             33,494               Gain                                                                                                                                 *de novo*

                                                                                                                                    arr\[GRCh37\] 19p13.3(260911_1247822)x1                  987                  Loss                                                                                                                                  

  52    DD                                                                                                          3 y    M        arr\[GRCh37\] 12q12(44719567_46210900)x1                 1491                 Loss                                                                                                        ARID2                    *de novo*

  53    ID                                                                                                          7 y    F        arr\[GRCh37\] Xq27.3q28(145269560_149282242)x1           4013                 Loss                                                                                                        FMR1; AFF2; IDS          *de novo*

  54    DD                                                                                                          4 y    M        arr\[GRCh37\] 2q22.3(144457537_145255844)x1              798                  Loss                                                                                                        ZEB2                     *de novo*

  55    ID                                                                                                          16 y   M        arr\[GRCh37\] Xq28(154476199_155233098)x1                759                  Loss                                                                                                        RAB39B                   Inherited from normal mother

  56    ID                                                                                                          10 y   M        arr\[GRCh37\] 8p11.22(38344498_39172014)x3               8575                 Gain                                                                                                                                 *de novo*

  57    ID                                                                                                          10 y   M        arr\[GRCh37\] 1p36.33p36.32(1156338_2468052)x1           1302                 Loss                                                                                                        GNB1; GABRD              *de novo*

  58    ID                                                                                                          14 y   F        arr\[GRCh37\] 9q34.11(131231815_132005416)x1             774                  Loss                                                                                                        SPTAN1                   *de novo*

  59    ID                                                                                                          17 y   F        arr\[GRCh37\] 6q27(169471201_170914297)x1                1443                 Loss                                                                                                        ERMARD; TBP              *de novo*

  60    ID                                                                                                          12 y   F        arr\[GRCh37\] 1p36.33p36.32(849466_2516031)x1            1667                 Loss                                                                                                        GNB1; GABRD              *de novo*

  61    DD + MCA (short status)                                                                                     3 y    M        arr\[GRCh37\] Xp11.22(53359258_53647606)x2               288                  Gain                   Xp11.22-linked intellectual disability                                               HUWE1                    Inherited from normal mother

  62    DD + MCA (microtia, cleft palate, ventricular septal defect)                                                8 m    F        arr\[GRCh37\] 4p16.3(68345_3488721)x1                    3420                 Loss                   Wolf--Hirschhorn syndrome                                                                                     *de novo*

  63    DD + MCA (facial dysmorphism, supravalvular aortic stenosis (SVAS) and supravalvular pulmonary stenosis)    11 m   M        arr\[GRCh37\] 7q11.23(72718123_74136633)x1               1419                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  64    ID + MCA (facial dysmorphism, short status)                                                                 6 y    M        arr\[GRCh37\] 17p11.2(16657318_20287758)x1               3630                 Loss                   Smith--Magenis syndrome                                                              RAI1; FLCN               *de novo*

  65    DD + MCA (facial dysmorphism, short status)                                                                 9 m    M        arr\[GRCh37\] 7q11.23(72697461_74136633)x1               1439                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  66    ID + MCA (facial dysmorphism, short status)                                                                 16 y   F        arr\[GRCh37\] 17p11.2(16736261_20417235)x1               3681                 Loss                   Smith--Magenis syndrome                                                              RAI1; FLCN               *de novo*

  67    ID + MCA (facial dysmorphism, cleft palate, short status)                                                   6 y    F        arr\[GRCh37\] 7q11.23(72713282_74154209)x1               1441                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  68    DD + MCA (facial dysmorphism, muscular hypotonia)                                                           2 y    F        arr\[GRCh37\] 7p22.3p11.1(50943_58019983)hmz             57,969               LOH (maternal UPD7)    Silver--Russell syndrome                                                                                      *de novo*

  69    ID + MCA (ventricular septal defect)                                                                        5 y    F        arr\[GRCh37\] 15q11.2q13.1(22770421_28704050)x1          5934                 Loss                   Prader--Willi syndrome                                                               UBE3A                    *de novo*

  70    DD + MCA (facial dysmorphism, short status)                                                                 16 m   M        arr\[GRCh37\] 7q11.23(72697239_74136633)x1               1439                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  71    DD + MCA (facial dysmorphism, hypoplasia of the corpus callosum, ventricular septal defect, short status)   9 m    M        arr\[GRCh37\] 17p13.3(525_2780094)x1                     2780                 Loss                   Miller--Dieker syndrome                                                              PAFAH1B1                 de novo

  72    DD + MCA (facial dysmorphism, supravalvular aortic stenosis (SVAS), ventricular septal defect)              9 m    M        arr\[GRCh37\] 7q11.23(72713282_74136633)x1               1423                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  73    DD + MCA (muscular hypotonia, dysphagia, cryptorchidism)                                                    3 m    M        arr\[GRCh37\] 15q11.2q13.1(23290787_28540345)x1          5250                 Loss                   Prader--Willi syndrome                                                               UBE3A                    *de novo*

  74    DD + MCA (triangular shaped face, short status, body asymmetry)                                             13 m   F        arr\[GRCh37\] 7p22.3p11.1(50943_58019983)hmz             57,969               LOH (maternal UPD7)    Silver--Russell syndrome                                                                                      *de novo*

  75    DD + MCA (facial dysmorphism, cafe-au-lait spots, atrial septal defect)                                     18 m   M        arr\[GRCh37\] 17q11.2(29025996_30369402)x1               1343                 Loss                   NF1-microdeletion syndrome                                                           NF1                      *de novo*

  76    ID + MCA (facial dysmorphism, short status)                                                                 13 y   F        arr\[GRCh37\] 5p15.33p15.31(113576_9756329)x1            9643                 Loss                   Cri du chat syndrome (5p deletion)                                                                            *de novo*

  77    ID + MCA (facial dysmorphism, brachydactyly)                                                                9 y    F        arr\[GRCh37\] 2q37.3(239755969_242782258)x1              3026                 Loss                   2q37 monosomy                                                                        HDAC4                    *de novo*

  78    DD + MCA (hypertelorism, overgrowth)                                                                        5 m    F        arr\[GRCh37\] 15q24.3q26.3(78160033_102429040)x3         24,269               Gain                   15q26 overgrowth syndrome                                                                                     Paternal balanced\
                                                                                                                                                                                                                                                                                                                                                       translocation 46,XY,t(3; 15) (p26; q24)

                                                                                                                                    arr\[GRCh37\] 3p26.3(61891_1542088)x1                    1480                 Loss                                                                                                        CNTN6                     

  79    DD + MCA (facial dysmorphism, esophageal atresia, external auditory canal atresia)                          7 m    M        arr\[GRCh37\] 22q13.31q13.33(48283717_51197766)x1        2914                 Loss                   22q13 deletion syndrome (Phelan--Mcdermid syndrome)                                  SHANK3                   *de novo*

                                                                                                                                    arr\[GRCh37\] 9q34.2q34.3(136244652_141018648)x3         4774                 Gain                                                                                                        EHMT1                     

  80    ID + MCA (atrial septal defect, cleft palate, hearing impairment)                                           5 y    M        arr\[GRCh37\] 22q11.1q11.21(16888899_20716903)x3         3828                 Gain                   Cat eye syndrome                                                                                              Maternal balanced translocation 46,XX,t(11; 22) (q23.3; q11.2)

                                                                                                                                    arr\[GRCh37\] 11q23.3q25(116683754_134937416)x3          18,254               Gain                                                                                                                                  

  81    DD + MCA (polysyndactyly)                                                                                   7 m    M        arr\[GRCh37\] 16p11.2(29351825_30176508)x1               825                  Loss                   16p11.2 recurrent microdeletion                                                                               *de novo*

  82    DD + MCA (triangular shaped face, short status, muscular hypotonia)                                         14 m   F        arr\[GRCh37\] 7p22.3p11.1(50943_58019983)hmz             57,969               LOH (maternal UPD7)    Silver--Russell syndrome                                                                                      *de novo*

  83    ID + MCA (atrial septal defect, ventricular septal defect)                                                  9 y    M        arr\[GRCh37\] 22q11.21(18648855_21800471)x1              3152                 Loss                   22q11 deletion syndrome (velocardiofacial/DiGeorge syndrome)                         TBX1                     *de novo*

  84    DD + MCA (short status)                                                                                     3 y    M        arr\[GRCh37\] 15q11.2q13.1(23290787_28928730)x1          5638                 Loss                   Angelman syndrome                                                                    UBE3A                    *de novo*

  85    ID + MCA (congenital heart disease, polysyndactyly)                                                         16 y   F        arr\[GRCh37\] 22q11.21(18648855_21800471)x1              3152                 Loss                   22q11 deletion syndrome (velocardiofacial/DiGeorge syndrome)                         TBX1                     *de novo*

  86    DD + MCA (facial dysmorphism)                                                                               13 m   M        arr\[GRCh37\] 16p13.11(14913788_16282869)x3              1369                 Gain                   16p13.11 recurrent microduplication (neurocognitive disorder susceptibility locus)                            Inherited from normal mother

  87    DD + MCA (muscular hypotonia, ventricular septal defect, cryptorchidism)                                    3 m    M        arr\[GRCh37\] 15q11.2q13.1(23290787_28540345)x1          5250                 Loss                   Prader--Willi syndrome                                                               UBE3A                    *de novo*

  88    DD + MCA (cleft palate)                                                                                     3 y    M        arr\[GRCh37\] 16p11.2(29428531_30176508)x1               748                  Loss                   16p11.2 recurrent microdeletion                                                                               *de novo*

  89    ID + MCA (facial dysmorphism, cleft palate, polysyndactyly, short status)                                   11 y   M        arr\[GRCh37\] 17q21.31q21.32(43170339_44988790)x1        1818                 Loss                   17q21.31 recurrent microdeletion syndrome (Koolen--de Vries syndrome)                KANSL1                   *de novo*

  90    ID + MCA (short status)                                                                                     9 y    F        arr\[GRCh37\] 22q11.21(18648855_21800471)x1              3169                 Loss                   22q11 deletion syndrome (velocardiofacial/DiGeorge syndrome)                         TBX1                     *de novo*

  91    DD + MCA (cleft palate)                                                                                     3 y    F        arr\[GRCh37\] 16p13.11(15481747_16390970)x3              909                  Gain                   16p13.11 recurrent microduplication (neurocognitive disorder susceptibility locus)                            *de novo*

  92    ID + MCA (cleft palate)                                                                                     13 y   F        arr\[GRCh37\] 15q11.2q13.1(23281885_28526905)x3          5245                 Gain                   15q11-q13 duplication syndrome                                                                                Inherited from normal mother

                                                                                                                                    arr\[GRCh37\] 16p11.2(29428531_30176508)x1               748                  Loss                   16p11.2 recurrent microdeletion                                                                               Inherited from normal father

  93    DD + MCA (facial dysmorphism, catlike cry, ventricular septal defect, short status)                         3 m    F        arr\[GRCh37\] 5p15.33p13.3(113576_32114177)x1            32,001               Loss                   Cri du chat syndrome (5p deletion)                                                   TRIO; CTNND2             *de novo*

  94    DD + MCA (short status)                                                                                     11 m   F        arr\[GRCh37\] Xp22.33p22.31(168551_8030262)x1            7862                 Loss                   Leri--Weill dyschondrosteosis (LWD): SHOX deletion                                   SHOX; ARSE               *de novo*

  95    ID + MCA (cleft palate)                                                                                     6 y    F        arr\[GRCh37\] 7q11.23(72692112_74154209)x1               1462                 Loss                   Williams-Beuren syndrome                                                             ELN                      *de novo*

  96    ID + MCA(micrognathia)                                                                                      16 y   F        arr\[GRCh37\] 8p23.3p23.1(158048_10029980)x1             9872                 Loss                   8p23.1 deletion syndrome                                                             CSMD1                    *de novo*

  97    ID + MCA (atrial septal defect, microtia, polysyndactyly)                                                   7 y    M        arr\[GRCh37\] 5q34q35.3(162638031_180329359)x3           17,691               Gain                   5q35 recurrent (Sotos syndrome) region (includes NSD1)                               FBXW11                   Maternal balanced\
                                                                                                                                                                                                                                                                                                                                                       translocation 46,XX,t(5; 12) (q34; p13.32)

                                                                                                                                    arr\[GRCh37\] 12p13.33p13.32(173786_4264694)x1           4091                 Loss                   12p13.33 microdeletion syndrome                                                                                

  98    DD + MCA (cryptorchidism, short status)                                                                     19 m   M        arr\[GRCh37\] 4q34.1q35.2(174352834_190957460)x3         16605                Gain                                                                                                                                 *de novo*

                                                                                                                                    arr\[GRCh37\] Xp22.33p22.31(168551_6455151)x0            6287                 Loss                   Leri--Weill dyschondrosteosis (LWD): SHOX deletion                                   SHOX; ARSE                

  99    DD + MCA (gallbladder agenesis)                                                                             3 y    F        arr\[GRCh37\] 8p23.3p23.1(158048_7044046)x1              6686                 Loss                                                                                                        CSMD1                    *de novo*

                                                                                                                                    arr\[GRCh37\] 8p23.1p12(11936000_33616243)x3             21,860               Gain                                                                                                                                  

  100   ID + MCA (atrial septal defect, hypermyotonia)                                                              6 y    M        arr\[GRCh37\] 2p23.1p22.1(32046639_38823958)x1           6777                 Loss                                                                                                        SPAST                    *de novo*

  101   DD + MCA (hypoplasia of the corpus callosum)                                                                3 m    F        arr\[GRCh37\] 13q33.2q34(106348324_115107733)x1          8759                 Loss                                                                                                        CHAMP1; BSVD2            *de novo*

  102   ID + MCA (micrognathia, polysyndactyly)                                                                     14 y   F        arr\[GRCh37\] 18p11.32q11.2(136227_20989843)x3           20,854               Gain                                                                                                                                 Maternal balanced\
                                                                                                                                                                                                                                                                                                                                                       translocation 46,XX,t(18; 21) (q11.2; q21)

                                                                                                                                    arr\[GRCh37\] 21q11.2q21.1(15016486_20371429)x1          5355                 Loss                                                                                                                                  

  103   DD + MCA (hypermyotonia, blepharophimosis)                                                                  3 m    M        arr\[GRCh37\] 3q22.1q23(132876177_139772196)x1           6896                 Loss                                                                                                        FOXL2                    *de novo*

  104   DD + MCA (facial dysmorphism)                                                                               8 m    F        arr\[GRCh37\] 10p15.3p12.2(100047_23162330)x3            23,062               Gain                                                                                                                                 Paternal inversion 46,XY,inv(10) (p12q26)

                                                                                                                                    arr\[GRCh37\] 10q26.3(134248768_135426386)x1             1178                 Loss                                                                                                                                  

  105   DD + MCA (ventricular septal defect, aortic stenosis)                                                       21 m   M        arr\[GRCh37\] 7p21.1p11.2(16641066_56373573)x3           39,733               Gain                                                                                                                                 *de novo*

                                                                                                                                    arr\[GRCh37\] 4q13.1q13.2(65818383_68116457)x1           2298                 Loss                                                                                                                                  

  106   DD + MCA (facial dysmorphism, cryptorchidism)                                                               3 y    M        arr\[GRCh37\] 3q13.33q25.1(121200603_151876470)x3        30,676               Gain                                                                                                                                 *de novo*

  107   ID + MCA (facial dysmorphism)                                                                               3 y    M        arr\[GRCh37\] 14q12(28897081_31268243)x1                 2371                 Loss                   Rett syndrome                                                                        FOXG1                    *de novo*

  108   DD + MCA (atrial septal defect)                                                                             14 m   F        arr\[GRCh37\] 20p13(61661_2150330)x1                     2089                 Loss                                                                                                        CSNK2A1; PDYN            *de novo*

  109   DD + MCA (facial dysmorphism, overgrowth, body asymmetry)                                                   2 y    F        arr\[GRCh37\] Xq21.31q27.3(86577241_145860589)x3         59,283               Gain                   Pelizaeus--Merzbacher disease (carrier)                                              PLP1                     *de novo*

  110   DD + MCA (cryptorchidism, hypospadias)                                                                      3 m    M        arr\[GRCh37\] 5p14.3p12(19454082_45506818)x3             26,053               Gain                                                                                                                                 *de novo*

  111   DD + MCA (facial dysmorphism, bilateral single transverse palmar creases)                                   3 m    F        arr\[GRCh37\] 9p24.3q13(208454_68216577)x3               10,188               Gain                   Chromosome 9p trisomy                                                                                         *de novo*

  112   ID + MCA (facial dysmorphism, webbed neck, low-set ears)                                                    5 y    F        arr\[GRCh37\] Xp22.33p11.22(168551_52706689)x1           52,538               Loss                                                                                                                                 *de novo*

                                                                                                                                    arr\[GRCh37\] Xp11.22q28(52833230_155233098)x3           102,400              Gain                                                                                                                                  

  113   ID + ASD                                                                                                    13 y   F        arr\[GRCh37\] 17p11.2(16657318_20463423)x1               3806                 Loss                   Smith--Magenis syndrome                                                              RAI1; FLCN               *de novo*

  114   DD + ASD                                                                                                    3 y    M        arr\[GRCh37\] 17p11.2 (16745600_20417235)x3              3672                 Gain                   Potocki--Lupski syndrome (17p11.2 duplication syndrome)                                                       *de novo*

  115   ID + ASD                                                                                                    10 y   M        arr\[GRCh37\] 2q37.2q37.3(235790877_242782258)x1         6991                 Loss                   2q37 monosomy                                                                        HDAC4                    Paternal inversion 46,XY,inv(2) (p24q37.2)

                                                                                                                                    arr\[GRCh37\] 2p25.3p24.3(12770_12658812)x3              12,646               Gain                                                                                                                                  

  116   ID + epilepsy (ichthyosis)                                                                                  12 y   M        arr\[GRCh37\] Xp22.31(6455151_8141076)x0                 1686                 Loss                   Steroid sulphatase deficiency (STS)                                                  STS                      Inherited from normal mother

  117   ID + epilepsy                                                                                               8 y    M        arr\[GRCh37\] 15q11.2q13.1(22770421_28704050)x1          5934                 Loss                   Angelman syndrome                                                                    UBE3A                    *de novo*

  118   DD + epilepsy                                                                                               3 y    F        arr\[GRCh37\] 16p13.12p13.11(14777379_16533107)x1        1756                 Loss                   16p13.11 recurrent microdeletion (neurocognitive disorder susceptibility locus)                               *de novo*

  119   ID + epilepsy                                                                                               6 y    M        arr\[GRCh37\] 15q11.2q13.1(23620191_28526905)x1          4907                 Loss                   Angelman syndrome                                                                    UBE3A                    *de novo*

  120   DD + epilepsy                                                                                               3 y    F        arr\[GRCh37\] 16p11.2(28557432_30176508)x1               1619                 Loss                   16p11.2 microduplication syndrome                                                    SH2B1                    *de novo*

  121   DD + epilepsy                                                                                               11 m   F        arr\[GRCh37\] 20q13.33(61485437_62790113)x1              1305                 Loss                                                                                                        CHRNA4; KCNQ2            *de novo*

  122   ID + epilepsy                                                                                               5 y    F        arr\[GRCh37\] 13q33.3q34(108237906_115107733)x1          6870                 Loss                                                                                                        CHAMP1; BSVD2            *de novo*

  123   DD + epilepsy                                                                                               4 y    F        arr\[GRCh37\] Xq23q24(111170674_117964845)x1             6794                 Loss                                                                                                                                 *de novo*

  124   ID + epilepsy                                                                                               8 y    M        arr\[GRCh37\] Xp22.13p21.3(17125886_28993521)x2          11,868               Gain                                                                                                                                 *de novo*

  125   ID + epilepsy                                                                                               6 y    M        arr\[GRCh37\] 2p24.3p24.2(15850097_16790467)x1           940                  Loss                                                                                                        MYCN                     *de novo*

  126   ID + epilepsy                                                                                               3 y    M        arr\[GRCh37\] 2q24.3(164444391_168745074)x1              4301                 Loss                                                                                                        SCN1A; SCN2A; SCN9A      *de novo*

  127   ID + epilepsy                                                                                               6 y    M        arr\[GRCh37\] 1p36.33(849466_2226509)x1                  1377                 Loss                                                                                                        GNB1; GABRD              *de novo*
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOH: loss of heterozygosity; UPD: uniparental disomy.

###### 

Microdeletion/microduplication syndromes in the 76 patients.

  Syndromes                                                                            Isolated DD/ID   DD/ID with MCA   DD/ID with ASD   DD/ID with epilepsy   Total
  ------------------------------------------------------------------------------------ ---------------- ---------------- ---------------- --------------------- -------
  Williams-Beuren syndrome                                                             7                6                0                0                     13
  Angelman syndrome                                                                    4                1                0                2                     7
  Silver--Russell syndrome                                                             0                3                0                0                     3
  15q11-q13 duplication syndrome                                                       2                1                0                0                     3
  16p11.2 recurrent microdeletion                                                      0                3                0                0                     3
  16p13.11 recurrent microduplication (neurocognitive disorder susceptibility locus)   1                2                0                0                     3
  22q11 deletion syndrome (velocardiofacial/DiGeorge syndrome)                         0                3                0                0                     3
  8p23.1 deletion syndrome                                                             2                1                0                0                     3
  Prader--Willi syndrome                                                               0                3                0                0                     3
  Smith--Magenis syndrome                                                              0                2                1                0                     3
  22q13 deletion syndrome (Phelan--Mcdermid syndrome)                                  2                1                0                0                     3
  2q37 monosomy                                                                        0                1                1                0                     2
  Cri du chat syndrome (5p deletion)                                                   0                2                0                0                     2
  Leri--Weill dyschondrosteosis (LWD): SHOX deletion                                   0                2                0                0                     2
  Potocki--Lupski syndrome (17p11.2 duplication syndrome)                              1                0                1                0                     2
  Wolf--Hirschhorn syndrome                                                            1                1                0                0                     2
  Xq28 (MECP2) duplication                                                             2                0                0                0                     2
  Cat eye syndrome                                                                     0                1                0                0                     1
  12p13.33 microdeletion syndrome                                                      0                1                0                0                     1
  15q24 recurrent microdeletion syndrome                                               1                0                0                0                     1
  15q26 overgrowth syndrome                                                            0                1                0                0                     1
  16p11.2 microduplication syndrome                                                    0                0                0                1                     1
  16p13.11 recurrent microdeletion (neurocognitive disorder susceptibility locus)      0                0                0                1                     1
  17q21.31 recurrent microdeletion syndrome (Koolen--de Vries syndrome)                0                1                0                0                     1
  1q43-q44 deletion syndrome                                                           1                0                0                0                     1
  22q11 duplication syndrome                                                           1                0                0                0                     1
  ATR-16 syndrome                                                                      1                0                0                0                     1
  Lamb-Shaffer syndrome                                                                1                0                0                0                     1
  Miller--Dieker syndrome                                                              0                1                0                0                     1
  NF1-microdeletion syndrome                                                           1                0                0                0                     1
  Pelizaeus--Merzbacher disease (carrier)                                              0                1                0                0                     1
  Potocki--Shaffer syndrome                                                            1                0                0                0                     1
  Rett syndrome                                                                        0                1                0                0                     1
  Steroid sulphatase deficiency (STS)                                                  0                0                0                1                     1
  Xp11.22-linked intellectual disability                                               0                1                0                0                     1
  Total                                                                                29               40               3                5                     77
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